End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
284,000 KRW | +0.89% | -2.91% | -19.43% |
May. 16 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
May. 08 | Invion Partners with Hanlim Pharma for Glioblastoma Treatment | MT |
Business Summary
Number of employees: 2,238
Sales per Business
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Medicine
73.0
%
| 975,021 | 73.2 % | 1,087,780 | 73.0 % | +11.56% |
Overseas Medicine
26.7
%
| 350,640 | 26.3 % | 397,513 | 26.7 % | +13.37% |
Drug Substance
0.4
%
| 5,885 | 0.4 % | 5,594 | 0.4 % | -4.95% |
Sales per region
KRW in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
South Korea
59.7
%
| 826,082 | 62.0 % | 890,760 | 59.7 % | +7.83% |
China
27.2
%
| 356,108 | 26.7 % | 404,849 | 27.2 % | +13.69% |
Other
5.1
%
| 63,687 | 4.8 % | 75,478 | 5.1 % | +18.51% |
United States
4.6
%
| 40,869 | 3.1 % | 67,990 | 4.6 % | +66.36% |
Japan
3.5
%
| 44,800 | 3.4 % | 51,811 | 3.5 % | +15.65% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Jong-Yoon Lim
CEO | Chief Executive Officer | 51 | - |
In-Guk Hwang
CMP | Compliance Officer | 52 | - |
Gwi-Hyun Seo
CTO | Chief Tech/Sci/R&D Officer | 62 | - |
Gwan-Sun Lee
BRD | Director/Board Member | 64 | - |
Gyu-Chan Kwon
PRN | Corporate Officer/Principal | 54 | - |
Yeong-Hoon Kim
PRN | Corporate Officer/Principal | 62 | - |
Ju-Hyun Lim
PRN | Corporate Officer/Principal | 49 | - |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Jong-Yoon Lim
CEO | Chief Executive Officer | 51 | - |
Gwan-Sun Lee
BRD | Director/Board Member | 64 | - |
Dong-Cheol Seo
BRD | Director/Board Member | 68 | 17-03-09 |
Seon-Hye Hwang
BRD | Director/Board Member | 70 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 12,810,991 | 6,518,514 ( 50.88 %) | 130,777 ( 1.021 %) | 50.88 % |
Holdings
Name | Equities | % | Valuation |
---|---|---|---|
HANMI PHARM. CO., LTD. 0.98% | 125,329 | 0.98% | 25,662,325 $ |
APTOSE BIOSCIENCES INC. 18.33% | 2,989,415 | 18.33% | 2,914,680 $ |
Company contact information
Hanmi Pharmaceutical Co., Ltd.
214 Muha-ro Paltan-myeon
18536, Hwaseong-si
+82 3 1350 5600
http://www.hanmipharm.comSector
Sales per Business
Sales per region
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.43% | 2.59B | |
+19.64% | 43.03B | |
+23.86% | 22.7B | |
+17.29% | 15.07B | |
+23.64% | 14.77B | |
+59.16% | 13.05B | |
-0.05% | 6.79B | |
-14.19% | 6.58B | |
-8.87% | 5.73B | |
+13.42% | 5.5B |
- Stock Market
- Equities
- A128940 Stock
- Company Hanmi Pharm. Co., Ltd.